Related by context. Frequent words. (Click for all words.) 66 Presents Positive 66 Application BLA 66 supplemental Biologics License Application 65 submitted Biologics License 65 NASDAQ CRXL 65 Completes Enrollment 64 Crucell NV Euronext 64 Application MAA 64 FDA Accepts 64 Company Nasdaq PRGO 63 refractory chronic lymphocytic 63 Act PDUFA date 63 Inc. Nasdaq IMGN 63 Nasdaq VRTX 62 Pivotal Phase III 62 Generic Version 61 Initiates Phase 61 Phase III Clinical Trial 61 submitted Marketing Authorization 61 application sNDA 60 CoTherix Inc. 60 Biologics License Application 60 Pivotal Trial 60 EPIX Pharmaceuticals Inc. 60 Ixempra 60 NASDAQ SHPGY 59 HAYWARD Calif. BUSINESS WIRE 59 Oral Solution 59 ACADIA Pharmaceuticals 59 sBLA 59 Patient Enrollment 59 Pivotal Phase 59 Phase III Trial 58 Initiate Phase 58 Inc. NASDAQ MRNA 58 Oscient Pharmaceuticals Corporation 58 Celsion Corporation 58 Patent Covering 58 Regains Compliance 58 ISTA Pharmaceuticals 58 ALIM 58 Orphan Drug designation 58 OTCQX RHHBY 58 Biologics License Application BLA 58 Andrx Corporation 58 BPAX 57 ZALBIN 57 sNDA 57 Cornerstone Therapeutics Inc. 57 Icatibant 57 Surgical Adhesive 57 TYGACIL 57 BioSpecifics Technologies Corp. 57 Protalix BioTherapeutics 57 Clofarabine 57 Nastech Pharmaceutical Company 57 CE Marked 57 Dynavax Technologies Corporation 57 FDA Clearance 57 humanized anti 57 Orphan Drug status 56 Patent Issued 56 Drug Applications ANDAs 56 REVLIMID lenalidomide 56 Nasdaq AMLN 56 Panzem R 56 Pirfenidone 56 Fluidigm Corporation 56 CYTR 56 Completes Tender Offer 56 Regains Compliance With 56 VALSTAR 56 Genelabs Technologies Inc. 56 CryoSeal FS System 56 ENZN 56 Palatin Technologies Inc. 56 Files Annual Report 56 Stockholders Approve Merger 56 FDA Approval 56 Neose Technologies Inc. 56 Ligand Pharmaceuticals Incorporated 56 Junovan 56 Idera Pharmaceuticals 55 Q2 Loss Narrows 55 OSIR 55 post herpetic neuralgia PHN 55 AVEO Pharmaceuticals 55 injection USP 55 NASDAQ IMCL 55 Rebif ® 55 Metabasis Therapeutics Inc. 55 ISTA Pharmaceuticals Inc. 55 IDEV 55 VICL 55 Marketing Authorization Application 55 Nexavar ® 55 PHARM 55 Orphan Drug Designation 55 Clinical Trial Application 55 Merck KGaA Darmstadt Germany 55 Zolinza